Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Menstrual and Reproductive History in Neuromyelitis Optica Spectrum Disorder (NMOSD): a cross-sectional analysis using the EnvIMS questionnaire
Multiple Sclerosis
P14 - Poster Session 14 (8:00 AM-9:00 AM)
9-013
To describe menstrual and reproductive history in women with NMOSD. 
Risk factors for developing NMOSD remain largely unknown, except for a much higher risk in women. A previous uncontrolled international study did not find an association between hormonal exposures and age of NMOSD onset, although one-quarter of post-menopausal participants experienced onset within 2 years of menopause.  
This was a preliminary, cross-sectional analysis of NMOSD participants from two academic centers in Toronto, Canada, who were enrolled as part of a national case-control study examining risk factors for NMOSD. Participants completed an adapted version of the validated EnvIMS questionnaire, previously used in an multiple sclerosis (MS) international study enrolling 2,800 cases and 5,012 controls. Eligible participants met 2015 International Panel for NMOSD diagnostic (IPND) criteria. Both aquaporin-4 antibody (APQ4-IgG) positive and negative cases were included; MOG antibody-associated cases were excluded. Recruitment for this study is on-going. 
 Of 47 participants, 42 (89.4%) were female. Thirty-one (73.8%) of the women were AQP4-IgG positive. NMOSD onset was reported at a mean age of 43.8 (SD 14.8) years. Mean age at menarche was 13.5 years and was unchanged by excluding seronegative cases. Fifteen (35.7%) had menarche at >15 years. No correlation (r=0.14) was observed in the overall cohort between age at menarche and NMOSD onset. Mean age of menopause was 47.1 years overall, and 46.7 years in seropositive cases. Eight out of sixteen (50.0%) who reported NMOSD onset >45 years and age of menopause experienced NMOSD onset within 5 years of menopause. Thirteen (30.9%) reported never getting pregnant and 10 (25.0%) had lost at least one pregnancy. 
Onset of menopause and late menarche may be risk factors for developing NMOSD in women. These preliminary findings will be explored in a larger Canadian national cohort, and against MS and unaffected control groups. 
Authors/Disclosures

PRESENTER 		No disclosure on file
Liesly Lee, MD (Sunnybrook Health Sciences Centre) Dr. Lee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Aventis. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Dina Dababneh, MD No disclosure on file
Dalia Rotstein, MD Dr. Rotstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. The institution of Dr. Rotstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Rotstein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Rotstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen/Horizon . Dr. Rotstein has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion . Dr. Rotstein has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Rotstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Aventis. Dr. Rotstein has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Dr. Rotstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Rotstein has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Rotstein has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion . Dr. Rotstein has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Rotstein has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amgen. The institution of Dr. Rotstein has received research support from MS Canada. The institution of Dr. Rotstein has received research support from National MS Society. Dr. Rotstein has received research support from Li Ka Shing Knowledge Institute. The institution of Dr. Rotstein has received research support from University of Toronto Division of Neurology. The institution of Dr. Rotstein has received research support from Canada's Drug Agency. The institution of Dr. Rotstein has received research support from Amgen. The institution of Dr. Rotstein has received research support from Alexion. The institution of Dr. Rotstein has received research support from Guthy Jackson Foundation .